Successful cross-protective efficacy induced by heat-adapted live attenuated nephropathogenic infectious bronchitis virus derived from a natural recombinant strain
A natural recombinant nephropathogenic K40/09 strain of infectious bronchitis virus (IBV) was heat-adapted for possible future use as live attenuated vaccine. The K40/09 strain was selected during successive serial passages in specific-pathogen free (SPF) embryonated eggs at sub-optimal higher temperature (56°C). Unlike the parental strain, the attenuated strain, designated K40/09 HP50, was found to be safe in 1-day-old SPF chicks, which showed neither mortality nor signs of morbidity, and rarely induced ciliostasis or histological changes in the trachea and kidney after intraocular and fine-spray administration. K40/09 HP50 provided almost complete protection against two distinct subgroups of a nephropathogenic strain (KM91-like and QX-like subgroup) and elicited the production of high titers of neutralizing antibody (neutralization index of 3.6). We conclude that the K40/09 HP50 vaccine virus is rapidly attenuated by heat adaptation and exhibits the desired level of attenuation, immunogenicity, and protective efficacy required for a live attenuated vaccine. These results indicate that the K40/09 vaccine could be helpful for the reduction of economic losses caused by recently emergent nephropathogenic IBV infection in many countries..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2015 |
---|---|
Erschienen: |
2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
Vaccine - 33(2015), 51, Seite 7370 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lim, Tae-Hyun [VerfasserIn] |
---|
Links: |
---|
doi: |
10.1016/j.vaccine.2015.07.043 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC1956705589 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1956705589 | ||
003 | DE-627 | ||
005 | 20230714141736.0 | ||
007 | tu | ||
008 | 160206s2015 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2015.07.043 |2 doi | |
028 | 5 | 2 | |a PQ20160617 |
035 | |a (DE-627)OLC1956705589 | ||
035 | |a (DE-599)GBVOLC1956705589 | ||
035 | |a (PRQ)p1934-fa34c5bff99a9c68f272688f175d71b4ff46838aa01cda8256a0046c426f6d0e0 | ||
035 | |a (KEY)0128923320150000033005107370successfulcrossprotectiveefficacyinducedbyheatadap | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q DNB |
100 | 1 | |a Lim, Tae-Hyun |e verfasserin |4 aut | |
245 | 1 | 0 | |a Successful cross-protective efficacy induced by heat-adapted live attenuated nephropathogenic infectious bronchitis virus derived from a natural recombinant strain |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a A natural recombinant nephropathogenic K40/09 strain of infectious bronchitis virus (IBV) was heat-adapted for possible future use as live attenuated vaccine. The K40/09 strain was selected during successive serial passages in specific-pathogen free (SPF) embryonated eggs at sub-optimal higher temperature (56°C). Unlike the parental strain, the attenuated strain, designated K40/09 HP50, was found to be safe in 1-day-old SPF chicks, which showed neither mortality nor signs of morbidity, and rarely induced ciliostasis or histological changes in the trachea and kidney after intraocular and fine-spray administration. K40/09 HP50 provided almost complete protection against two distinct subgroups of a nephropathogenic strain (KM91-like and QX-like subgroup) and elicited the production of high titers of neutralizing antibody (neutralization index of 3.6). We conclude that the K40/09 HP50 vaccine virus is rapidly attenuated by heat adaptation and exhibits the desired level of attenuation, immunogenicity, and protective efficacy required for a live attenuated vaccine. These results indicate that the K40/09 vaccine could be helpful for the reduction of economic losses caused by recently emergent nephropathogenic IBV infection in many countries. | ||
540 | |a Nutzungsrecht: Copyright © 2015 Elsevier Ltd. All rights reserved. | ||
650 | 4 | |a Poultry | |
650 | 4 | |a Safety | |
650 | 4 | |a Viruses | |
650 | 4 | |a Disease control | |
650 | 4 | |a Laboratory animals | |
650 | 4 | |a Infectious bronchitis virus | |
650 | 4 | |a Attenuation | |
650 | 4 | |a Animal vaccines | |
650 | 4 | |a Studies | |
650 | 4 | |a Kidneys | |
650 | 4 | |a Immunization | |
650 | 4 | |a Cross-protective efficacy | |
650 | 4 | |a RNA polymerase | |
650 | 4 | |a Heat adaptation | |
650 | 4 | |a Animal diseases | |
700 | 1 | |a Youn, Ha-Na |4 oth | |
700 | 1 | |a Yuk, Seong-Su |4 oth | |
700 | 1 | |a Kwon, Jung-Hoon |4 oth | |
700 | 1 | |a Hong, Woo-Tack |4 oth | |
700 | 1 | |a Gwon, Gyeong-Bin |4 oth | |
700 | 1 | |a Lee, Jung-Ah |4 oth | |
700 | 1 | |a Lee, Joong-Bok |4 oth | |
700 | 1 | |a Lee, Sang-Won |4 oth | |
700 | 1 | |a Song, Chang-Seon |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Vaccine |d Amsterdam : Elsevier, 1983 |g 33(2015), 51, Seite 7370 |w (DE-627)130402427 |w (DE-600)605674-X |w (DE-576)015904938 |x 0264-410X |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2015 |g number:51 |g pages:7370 |
856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.vaccine.2015.07.043 |3 Volltext |
856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26218899 |
856 | 4 | 2 | |u http://search.proquest.com/docview/1746587045 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4219 | ||
951 | |a AR | ||
952 | |d 33 |j 2015 |e 51 |h 7370 |